-
Full text
Comparison of serum paraoxonase and arylesterase activities between iron deficiency anemia patients and chronic kidney disease patients with anemia.
Okuturlar Y, Akalin N, Kaptanogullari OH, Guner NT, Yilmaz D, Gedikbasi A, Soyluk O, Mert M, Serin SO, Kocoglu H, Hursitoglu M, Kumbasar A.
Ren Fail. 2016 Jun;38(5):781-6. doi: 10.3109/0886022X.2016.1162080. Epub 2016 Apr 6.
-
Pub MED
Diagnosis of Iron-Deficiency Anemia in Chronic Kidney Disease.
Bahrainwala J, Berns JS.
Semin Nephrol. 2016 Mar;36(2):94-8. doi: 10.1016/j.semnephrol.2016.02.002.
-
Full text
Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia.
Kalra PA, Bhandari S.
Int J Nephrol Renovasc Dis. 2016 Mar 10;9:53-64. doi: 10.2147/IJNRD.S89704. eCollection 2016.
-
Pub MED
The Labile Side of Iron Supplementation in CKD.
Slotki I, Cabantchik ZI.
J Am Soc Nephrol. 2015 Nov;26(11):2612-9. doi: 10.1681
-
Pub MED
New Options for Iron Supplementation in Maintenance Hemodialysis Patients.
Vaziri ND, Kalantar-Zadeh K, Wish JB.
Am J Kidney Dis. 2015 Nov 23. pii:S0272-6386(15)01322-0. doi: 10.1053/j.ajkd.2015.09.031.
-
Full text
Target Hemoglobin May Be Achieved with Intravenous Iron Alone in Anemic Patients with Cardiorenal Syndrome: An Observational Study.
Ben-Assa E, Shacham Y, Shashar M, Leshem-Rubinow E, Gal-Oz A, Schwartz IF, Schwartz D, Silverberg DS, Chernin G.
Cardiorenal Med. 2015 Oct;5(4):246-53
-
Pub MED
Is Intravenous Iron Supplementation Safe to Administer to Patients on Hemodialysis with Active Infection-What Do We Know, and What More Do We Need to Know?
Bennett CL, Hermanson T.
Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1714-5. doi: 10.2215/CJN.08060715
-
Pub MED
Bone marrow iron distribution, hepcidin, and ferroportin expression in renal anemia.
Bârsan L, Stanciu A, Stancu S, Căpuşă C, Brătescu L, Mandache E, Radu E, Mircescu G.
Hematology. 2015 Oct;20(9):543-52. doi: 10.1179/1607845415Y.0000000004.
-
Full text
Oral or intravenous iron for anemia correction in chronic kidney disease?
Drüeke TB, Massy ZA.
Kidney Int. 2015 Oct;88(4):673-5. doi:10.1038/ki.2015.189. PubMed PMID: 26422625.
-
Full text
A randomized trial of intravenous and oral iron in chronic kidney disease.
Agarwal R, Kusek JW, Pappas MK.
Kidney Int. 2015 Oct;88(4):905-14. doi:10.1038/ki.2015.163. Epub 2015 Jun 17.
-
Pub MED
How to Supplement Iron in Patients with Renal Anemia.
Tanaka S, Tanaka T.
Nephron. 2015;131(2):138-44. doi: 10.1159/000440773.
-
Pub MED
How the Target Hemoglobin of Renal Anemia Should Be.
Mimura I, Tanaka T, Nangaku M.
Nephron. 2015;131(3):202-9. doi: 10.1159/000440849. Epub 2015 Sep 19.
-
Full text
Managing hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: latest evidence and clinical usefulness.
Yagil Y, Fadem SZ, Kant KS, Bhatt U, Sika M, Lewis JB, Negoi D.
Ther Adv Chronic Dis. 2015 Sep;6(5):252-63. doi: 10.1177/2040622315589934. Review.
-
Full text
Effects of carnitine on oxidative stress response to intravenous iron administration to patients with CKD: impact of haptoglobin phenotype.
Armaly Z, Abd El Qader A, Jabbour A, Hassan K, Ramadan R, Bowirrat A, Bisharat B.
BMC Nephrol. 2015 Aug 13;16:135. doi: 10.1186/s12882-015-0119-0.
-
Full text
A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.
Kalra PA, Bhandari S, Saxena S, Agarwal D, Wirtz G, Kletzmayr J, Thomsen LL, Coyne DW.
Nephrol Dial Transplant. 2015 Aug 6. pii: gfv293.
-
Pub MED
Iron therapy in chronic kidney disease: Recent changes, benefits and risks.
Ribeiro S, Belo L, Reis F, Santos-Silva A.
Blood Rev. 2015 Aug 18. pii: S0268-960X(15)00062-4. doi: 10.1016/j.blre.2015.07.006
-
Full text
The safety and efficacy of high dose ferric carboxymaltose in patients with chronic kidney disease: A single center study.
Vikrant S, Parashar A.
Indian J Nephrol. 2015 Jul-Aug;25(4):213-21. doi: 10.4103/0971-4065.144421.
-
Pub MED
Outcomes Associated with Conventional Accelerated Versus Once-Weekly IV Iron Therapy in Outpatients Undergoing Hemodialysis.
Malkinska M, El Nekidy WS, El-Masri MM, Kadri A, Donaldson C, Soong D.
Can J Hosp Pharm. 2015 Jul-Aug;68(4):304-10.
-
Pub MED
Relationship between hepcidin and GDF15 in anemic patients with type 2 diabetes without overt renal impairment.
Hong JH, Choi YK, Min BK, Park KS, Seong K, Lee IK, Kim JG.
Diabetes Res Clin Pract. 2015 Jul;109(1):64-70. doi: 10.1016/j.diabres.2015.05.001
-
Pub MED
Considerations and challenges in defining optimal iron utilization in hemodialysis
Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S; Dialysis Advisory Group of the American Society of Nephrology
J Am Soc Nephrol. 2015 Jun;26(6):1238-47. doi: 10.1681/ASN.2014090922.
-
Pub MED
A randomized trial of intravenous and oral iron in chronic kidney disease
Rajiv Agarwal, John W Kusek and Maria K Pappas
Kidney Int. doi:10.1038/ki.2015.163
-
Pub MED
Dysregulated iron metabolism in patients on hemodialysis.
Nakanishi T, Hasuike Y, Otaki Y, Nanami M, Kuragano T.
Contrib Nephrol. 2015;185:22-31. doi: 10.1159/000380967
-
Pub MED
Renal functional and structural integrity in infants with iron deficiency anemia: relation to oxidative stress and response to iron therapy.
El-Shimi MS, El-Farrash RA, Ismail EA, El-Safty A, Nada AS, El-Gamel OA, Salem YM, Shoukry SM.
Pediatr Nephrol.
-
Pub MED
Heme iron polypeptide for the management of anaemia of chronic kidney disease.
Dull RB, Davis E
J Clin Pharm Ther. 2015 Aug;40(4):386-90. doi: 10.1111/jcpt.12281.
-
Pub MED
Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial.
Pisani A, Riccio E, Sabbatini M, Andreucci M, Del Rio A, Visciano B.
Nephrol Dial Transplant. 2015 Apr;30(4):645-52. doi: 10.1093/ndt/gfu357.
-
Full text
Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?
Negri AL, Ureña Torres PA
Clin Kidney J. 2015 Apr;8(2):161-7. doi: 10.1093/ckj/sfu139
-
Pub MED
Iron supplementation associates with low mortality in pre-dialyzed advanced chronic kidney disease patients receiving erythropoiesis-stimulating agents: a nationwide database analysis
Kuo KL, Hung SC, Liu JS, Chang YK, Hsu CC, Tarng C.
Nephrol Dial Transplant. DOI: doi: 10.1093/ndt/gfv085
-
Full text
Effect of Paricalcitol vs Calcitriol on Hemoglobin Levels in Chronic Kidney Disease Patients: A Randomized Trial.
Riccio E, Sabbatini M, Bruzzese D, Capuano I, Migliaccio S, Andreucci M, Pisani A.
PLoS One. 2015 Mar 17;10(3):e0118174. doi: 10.1371/journal.pone.0118174. eCollection 2015.
-
Full text
Serum hepcidin levels in patients with end-stage renal disease on hemodialysis.
Rubab Z, Amin H, Abbas K, Hussain S, Ullah MI, Mohsin S.
Saudi J Kidney Dis Transpl. 2015 Jan;26(1):19-25.
-
Full text
Changes in Echocardiographic Parameters in Iron Deficiency Patients with Heart Failure and Chronic Kidney Disease Treated with Intravenous Iron.
Toblli JE, Di Gennaro F, Rivas C.
Heart Lung Circ. 2015 Jan 21. pii: S1443-9506(15)00034-7. doi: 10.1016/j.hlc.2014.12.161. [Epub ahead of print].
-
Full text
C.E.R.A. administered once monthly corrects and maintains stable hemoglobin levels in chronic kidney disease patients not on dialysis: the observational study MICENAS II.
Martínez-Castelao A, Cases A, Coll E, Bonal J, Galceran JM, Fort J, Moreso F, Torregrosa V, Guirado L, Ruiz P; Investigators of the Micenas II study.
Nefrologia. 2015;35(1):80-6. doi: 10.3265/Nefrologia.pre2014.Sep.12588. Epub 2014 Oct 22.
-
Link
Iron supplementation and mortality in incident dialysis patients: an observational study.
Zitt E, Sturm G, Kronenberg F, Neyer U, Knoll F, Lhotta K, Weiss G.
PLoS One. 2014 Dec 2;9(12):e114144
-
Full text
Hepcidin-25, mean corpuscular volume, and ferritin as predictors of response to oral iron supplementation in hemodialysis patients.
Takasawa K, Takaeda C, Maeda T, Ueda N.
Nutrients. 2014 Dec 29;7(1):103-18. doi: 10.3390/nu7010103.
-
Pub MED
Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study.
Tangri N, Miskulin DC, Zhou J, Bandeen-Roche K, Michels WM, Ephraim PL, McDermott A, Crews DC, Scialla JJ, Sozio SM, Shafi T, Jaar BG, Meyer K, Ebony Boulware L; for The DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators.
Nephrol Dial Transplant. 2014 Nov 2. pii: gfu349. [Epub ahead of print]
-
Pub MED
Intravenous iron exposure and mortality in patients on hemodialysis.
Miskulin DC, Tangri N, Bandeen-Roche K, Zhou J, McDermott A, Meyer KB, Ephraim PL, Michels WM, Jaar BG, Crews DC, Scialla JJ, Sozio SM, Shafi T, Wu AW, Cook C, Boulware LE; Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) Network Patient Outcomes in End Stage Renal Disease Study Investigators.
Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1930-9.
-
Pub MED
Malondialdehyde, antioxidant enzymes, and renal tubular functions in children with iron deficiency or iron-deficiency anemia.
Altun D, Kurekci AE, Gursel O, Hacihamdioglu DO, Kurt I, Aydin A, Ozcan O.
Biol Trace Elem Res. 2014 Oct;161(1):48-56. doi: 10.1007/s12011-014-0084-7. Epub 2014 Aug 8.
-
Pub MED
Intravenous iron administration is associated with reduced platelet counts in patients with chronic kidney disease.
Hazara AM, Bhandari S.
J Clin Pharm Ther. 2014 Oct 10.
-
Link
Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients.
Kuragano T, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T, Kitamura K, Fujimoto S, Hase H, Joki N, Fukatsu A, Inoue T, Itakura I, Nakanishi T.
Kidney Int. 2014 Oct;86(4):845-54.
-
Pub MED
Magnetic Resonance Imaging Repercussions of Intravenous Iron Products Used for Iron-Deficiency Anemia and Dialysis-Associated Anemia.
Rostoker G, Cohen Y.
J Comput Assist Tomogr. 2014 Sep 16. [Epub ahead of print]
-
Pub MED
Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: a replication study.
Freburger JK, Ellis AR, Kshirsagar AV, Wang L, Brookhart MA.
BMC Nephrol. 2014 Sep 22; 15:154
-
Pub MED
Safety of total dose iron dextran infusion in geriatric patients with chronic kidney disease and iron deficiency anemia.
Dossabhoy NR, Turley S, Gascoyne R, Tapolyai M, Sulaiman K.
Ren Fail. 2014 Aug;36(7):1033-7. doi: 10.3109/0886022X.2014.918785. Epub 2014 May 21.
-
Pub MED
Cumulative iron dose and resistance to erythropoietin.
Rosati A, Tetta C, Merello JI, Palomares I, Pérez-García R, Maduell F, Canaud B, Aljama García P.
J Nephrol. 2014 Aug 5. [Epub ahead of print]
-
Pub MED
The relationship of Prohepcidin levels with anemia and inflammatory markers in non-diabetic uremic patients: a controlled study.
Aydin Z, Gursu M, Karadag S, Uzun S, Sumnu A, Doventas Y, Ozturk S, Kazancioglu R.
Ren Fail. 2014 Jul 21:1-5. [Epub ahead of print]
-
Pub MED
Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality.
Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM.
Kidney Int. 2014 Jul 30. doi: 10.1038/ki.2014.275. [Epub ahead of print]
-
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
Macdougall IC, et al.
Nephrol Dial Transplant. 2014 Jun 2. pii: gfu201 [Epub ahead of print]
-
Full text
The Relation of Hepcidin to Iron Disorders, Inflammation and Hemoglobin in Chronic Kidney Disease.
Mercadel L, Metzger M, Haymann JP, Thervet E, Boffa JJ, Flamant M, Vrtovsnik F, Houillier P, Froissart M, Stengel B; the NephroTest Study Group.
PLoS One. 2014 Jun 30;9(6):e99781. doi: 10.1371/journal.pone.0099781. eCollection 2014.
-
Pub MED
Iron Metabolism in Transplantation.
Schaefer B, Effenberger M, Zoller H.
Transpl Int. 2014 Jun 25. doi: 10.1111/tri.12374. [Epub ahead of print]
-
Pub MED
New treatment approaches in chronic kidney disease-associated anaemia.
Del Vecchio L, Locatelli F.
Expert Opin Biol Ther. 2014 May;14(5):687-96. doi: 10.1517/14712598.2014.892577. Epub 2014 Mar 1.
-
Pub MED
Anemia in Chronic Kidney Disease Treating the Numbers, Not the Patients.
Coyne DW.
JAMA Intern Med. 2014 May;174(5):708-9.
-
Pub MED
Iron dosing in kidney disease: inconsistency of evidence and clinical practice.
Gaweda AE, et al.
Neprhol Dial Transplant, 2014; May.
-
Pub MED
Effects of additional iron doses on hepcidin-25 level in hemodialysis patients without evident iron deficiency.
Brätescu LO, et al.
Int Urol Nephrol, 2014; May: 46 (5): 1005-1012.
-
Pub MED
Hepcidin levels in chronic hemodialysis patients: a critical evaluation.
Valenti L, et al.
Clin Chem Lab Med, 2014; 52 (5): 613-619.
-
Full text
Distinct immunologic effects of different intravenous iron preparations on monocytes.
Fell LH, Zawada AM, Rogacev KS, Seiler S, Fliser D, Heine GH.
Nephrol Dial Transplant. 2014 Apr;29(4):809-22. doi: 10.1093/ndt/gft524. Epub 2014 Feb 11.
-
Pub MED
The ESA scenario gets complex: from biosimilar epoetins to activin traps.
Jelkmann W.
Nephrol Dial Transplant. 2014 Apr 19. [Epub ahead of print]
-
Pub MED
Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
Prats M, Font R, García C, Muñoz-Cortés M, Cabré C, Jariod M, Romeu M, Giralt M, Martinez-Vea A.
Clin Nephrol. 2014 Apr 2. [Epub ahead of print]
-
Pub MED
Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease.
Chand S, Ward DG, Ng ZY, Hodson J, Kirby H, Steele P, Rooplal I, Bantugon F, Iqbal T, Tselepis C, Drayson MT, Whitelegg A, Chowrimootoo M, Borrows R.
J Nephrol. 2014 Apr 1. [Epub ahead of print]
-
Full text
Regulation of Hepcidin-25 by Short- and Long-Acting rhEPO May Be Dependent on Ferritin and Predict the Response to rhEPO in Hemodialysis Patients.
Takasawa K, et al.
Nephron Extra, 2014; 4 (1): 55-63.
-
Full text
A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.
Macdougall IC, et al.
Clin J Am Soc Neprhol, 2014; 9 (4): 705-712.
-
Full text
Prevalencia de anemia y su manejo clínico en la enfermedad renal crónica estadios 3-5 no en diálisis en Cataluña: estudio MICENAS I.
Cases-Amenós A, Martínez-Castelao A, Fort-Ros J, Bonal-Bastons J, Ruiz MP, Vallés-Prats M, Coll-Piera E, Galcerán-Gui JM.
Nefrologia 2014;34(2):189-198 | Doi. 10.3265/Nefrologia.pre2013.Dec.12261.
-
Pub MED
The additive burden of iron deficiency in the cardiorenal-anaemia axis: scope of a problem and its consequences.
Klip IT, Jankowska EA, Enjuanes C, Voors AA, Banasiak W, Bruguera J, Rozentryt P, Polonski L, van Veldhuisen DJ, Ponikowski P, Comin-Colet J, van der Meer P.
Eur J Heart Fail. 2014 Mar 18. doi: 10.1002/ejhf.84. [Epub ahead of print]
-
Pub MED
Trends in Anemia Care in Older Patients Approaching End-Stage Renal Disease in the United States (1995-2010).
Winkelmayer WC, Mitani AA, Goldstein BA, Brookhart MA, Chertow GM.
JAMA Intern Med. 2014 Mar 3. doi: 10.1001/jamainternmed.2014.87. [Epub ahead of print]
-
Pub MED
The pathophysiology and pharmacology of hepcidin.
Ruchala P, Nemeth E.
Trends Pharmacol Sci. 2014 Mar;35(3):155-61. doi: 10.1016/j.tips.2014.01.004. Epub 2014 Feb 17.
-
The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients.
Zumbrennen-Bullough K, Babitt JL.
Nephrol Dial Transplant. 2014 Feb;29(2):263-73.
-
Pub MED
Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis.
Susantitaphong P, et al.
Am J Nephrol. 2014;39(2):130-41. doi: 10.1159/000358336. Epub 2014 Feb 7.
-
Full text
A 3-marker index improves the identification of iron disorders in CKD anaemia.
Mercadal L, Metzger M, Haymann JP, Thervet E, Boffa JJ, Flamant M, Vrtovsnik F, Gauci C, Froissart M, Stengel B; NephroTest Study Group.
PLoS One. 2014 Feb 19;9(2):e84144. doi: 10.1371/journal.pone.0084144. eCollection 2014.
-
Full text
Pathophysiology of anemia in chronic kidney diseases. A review.
Zadrazil J, Horak P.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014 Jan 3. doi: 10.5507/bp.2013.093.
-
Full text
Prevalence of anemia in chronic kidney disease in the United States.
Stauffer ME, Fan T.
PLoS One. 2014 Jan 2;9(1):e84943. doi: 10.1371/journal.pone.0084943.
-
Full text
Iron and infection in hemodialysis patients.
Ishida JH, Johansen KL.
Semin Dial. 2014 Jan;27(1):26-36. doi: 10.1111/sdi.12168.
-
Pub MED
Update on intravenous iron choices.
Larson DS, Coyne DW.
Curr Opin Nephrol Hypertens. 2014 Jan 7.
-
Full text
TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patients.
Gaweda AE, Bhat P, Maglinte GA, Chang CL, Hill J, Park GS, Ashfaq A, Gitlin M.
Hemodial Int. 2014 Jan;18(1):38-46. doi: 10.1111/hdi.12078.
-
Link
Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer.
Hazzan AD, Shah HH, Hong S, Sakhiya V, Wanchoo R, Fishbane S.
Kidney Int. 2014 Jan 8. doi: 10.1038/ki.2013.528.
-
Full text
Severe hypophosphataemia after intravenous iron administration.
Blazevic A, Hunze J, Boots JM.
Neth J Med. 2014 Jan;72(1):49-53.
-
Full text
Trends in anemia management in US hemodialysis patients 2004-2010.
Miskulin DC, Zhou J, Tangri N, Bandeen-Roche K, Cook C, Ephraim PL, Crews DC, Scialla JJ, Sozio SM, Shafi T, Jaar BG, Boulware LE; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators.
BMC Nephrol. 2013 Dec 1;14:264. doi: 10.1186/1471-2369-14-264.
-
Full text
New renal anemia drugs: is there really anything new on the horizon?
Malyszko J.
Expert Opin Emerg Drugs. 2013 Dec 18.
-
Pub MED
Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics.
Minutolo R, Locatelli F, Gallieni M, Bonofiglio R, Fuiano G, Oldrizzi L, Conte G, De Nicola L, Mangione F, Esposito P, Dal Canton A; REport of COmorbidities in non-Dialysis Renal Disease Population in Italy (RECORD-IT) Study Group.
Nephrol Dial Transplant. 2013 Dec;28(12):3035-45.
-
Full text
Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients.
Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA.
PLoS One. 2013 Nov 1;8(11):e78930. doi: 10.1371/journal.pone.0078930. eCollection 2013.
-
Link
Low hepcidin triggers hepatic iron accumulation in patients with hepatitis.
Hörl WH, Schmidt A.
Nephrol Dial Transplant. 2013 Nov 27.
-
Full text
Blood disorders after kidney transplantation.
Reindl-Schwaighofer R, Oberbauer R.
Transplant Rev (Orlando).2013 Oct 10. pii: S0955-470X(13)00108-0. doi: 10.1016/j.trre.2013.10.001.
-
Pub MED
Iron toxicity: relevance for dialysis patients.
Fishbane S, Mathew A, Vaziri ND.
Nephrol Dial Transplant.2013 Oct 28.
-
Pub MED
Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM.
Nephrol Dial Transplant. 2013 Oct;28(10):2570-9.
-
Full text
Iron deficiency anaemia in chronic kidney disease.
Wittwer I.
J Ren Care.2013 Sep;39(3):182-8. doi: 10.1111/j.1755-6686.2013.12026.x.
-
Link
Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.
Onken JE, Bregman DB, Harrington RA, Morris D, Buerkert J, Hamerski D, Iftikhar H, Mangoo-Karim R, Martin ER, Martinez CO, Newman GE, Qunibi WY, Ross DL, Singh B, Smith MT, Butcher A, Koch TA, Goodnough LT.
Nephrol Dial Transplant. 2013 Aug 20.
-
Full text
Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis.
Vaziri ND.
Am J Kidney Dis.2013 Jun;61(6):992-1000. doi: 10.1053/j.ajkd.2012.10.027.
-
Pub MED
Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients.
Brookhart MA, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Kshirsagar AV.
J Am Soc Nephrol. 2013 Jun;24(7):1151.
-
Full text
Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial.
Goldstein SL, Morris D, Warady BA.
Am J Kidney Dis.2013 Apr;61(4):588-97. doi: 10.1053/j.ajkd.2012.10.019.
-
Pub MED
Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
Charytan C, Bernardo MV, Koch TA, Butcher A, Morris D, Bregman DB.
Nephrol Dial Transplant.2013 Apr;28(4):953-64. doi: 10.1093/ndt/gfs528.
-
Pub MED
Greater potency of darbepoetin-α; than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
Shoji S, Inaba M, Tomosugi N, Okuno S, Ichii M, Yamakawa T, Kurihara S.
Eur J Haematol. 2013 Mar;90(3):237-44. doi: 10.1111/ejh.12067.
-
Pub MED
An economic evaluation of intravenous versus oral iron supplementation in people on haemodialysis.
Wong G, Howard K, Hodson E, Irving M, Craig JC.
Nephrol Dial Transplant.2013 Feb;28(2):413-20. doi: 10.1093/ndt/gfs487.
-
Full text
Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease: Future Research Needs: Identification of Future Research Needs From Comparative Effectiveness Review No. 83 [Internet].
Chung M, Chan JA, Moorthy D, Hadar N, Ratichek SJ, Concannon TW, Lau J.
Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Jan. Report No.: 13-EHC038-EF. AHRQ Comparative Effectiveness Reviews.
-
Full text
Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall IC, Geisser P.
Iran J Kidney Dis.2013 Jan;7(1):9-22.
Registrarse
